ProTides -
Transforming Chemo to
Targeted Therapy

 

The ProTide Technology Platform has been designed to target specific patient populations for whom chemotherapy is not effective.  ProTides significantly improve the efficacy (by overcoming the key resistance pathways), and lower the toxicity of established anticancer agents.
NuCana BioMed will apply the ProTide technology platform to specific pyrimidine and purine nucleoside analogues. These two distinct classes include all the nucleoside analogues currently approved for the treatment of cancer.
Initial development will focus on transforming gemcitabine to specifically target patients who are resistant to this widely used agent. Gemcitabine achieves responses in up to 20% of our target indications, and had combined sales of approximately $2 billion in 2009.
The ProTide technology has been validated by GSK, Roche, Gilead and Inhibitex in their enhancement of anti-viral nucleotides. Medicines derived from the ProTide technology are classed as New Chemical Entities.